Mac Bonafede, PhD, MPH

Real World Evidence

Mac Bonafede, PhD, MPH

Mac is a passionate researcher who enjoys collaborating to tackle research questions using real-world data. He is a proponent of team-based problem solving to address a wide range of healthcare research challenges.

AREA OF EXPERTISE

Health Economics and Outcomes Research Real World Data / Evidence Value-Based Care

Mac is Vice President of Real World Evidence at Veradigm where he leads an elite team of researchers, data scientists, statisticians, and epidemiologists in conducting and guiding real world health economics and outcomes research studies. Mac’s team is adept at using varied real world data sources to generate real world evidence findings in a range of therapeutic areas.

Before joining Veradigm, Mac was with IBM Watson Health (previously Truven Health Analytics and Thomson Reuters Healthcare). Prior to that, he served on the faculty of the Albany College of Pharmacy, where he taught courses covering research and statistical methods, total quality management, and evidence-based medicine.

Mac continues to lecture in the University of New Hampshire’s Department of Health Management and Policy. He holds a PhD in health services research and policy and a master’s degree in public health, both from the University of Rochester. Outside of work, Mac is likely to be found working on his family’s 200-year-old farmhouse in southern New Hampshire or unsuccessfully trying his hand at small scale agriculture and homesteading.

References to published articles by this expert

Thorat, T, McGarry, LJ, Bonafede, MM, et al. Healthcare resource utilization and costs among children with cystic fibrosis in the United States. Pediatric Pulmonology. 2021; 56: 2833- 2844.
Bedenbaugh AV, Bonafede M, Marchlewicz EH, Lee V, Tambiah J. Real-World Health Care Resource Utilization and Costs Among US Patients with Knee Osteoarthritis Compared with Controls. Clinicoecon Outcomes Res. 2021 May 21;13:421-435.
Manjelievskaia J, Boytsov N, Brouillette MA, Onyekwere U, Pierce E, Goldblum O, Bonafede M. The direct and indirect costs of adult atopic dermatitis. J Manag Care Spec Pharm. 2021 Oct;27(10):1416-1425.
Beyrer J, Manjelievskaia, Bonafede M, Lenhart G, Nolot S, Haldane D, Johnston J. Validation of an International Classification of Disease, 10th Revision Coding Adaptation for the Charlson Comorbidity Index in United States Healthcare Claims Data. Pharmacoepidemiol Drug Saf. 2021 May; 30(5):582-593.
Kantor D, Mehta R, Pelletier C, Tian M, Noxon V, Johnson BH, Bonafede M. Treatment Patterns and Relapses Among Newly Treated Multiple Sclerosis Patients From a Retrospective Claims Analysis. Clin Ther. 2020 Nov;42(11):2136-2147.
Bonafede M, Mehta R, Kim G, Sruti I, Tian M, Pelletier C, Goldfarb N. Productivity Loss and Associated Costs Among Employed Patients Receiving Disease-Modifying Treatment for Multiple Sclerosis. Pharmacoecon Open. 2021 Mar;5(1):23-34.
Schneider DB, Krajcer Z, Bonafede MM, Thoma E, Hasegawa J, Bhounsule P, Thiel E. Clinical and Economic Outcomes of ProGlide Compared to Surgical Repair of Large Bore Arterial Access. J Comp Eff Res. 2019 Dec;8(16): 1381-1392.
Bonafede MM, Miller JD, Pohlman SK, Troeger KA, Herschorn SD, Winer IH. Breast, Cervical, and Colorectal Cancer Screening: Patterns among Women with Medicaid and Commercial Insurance. American Journal of Preventive Medicine 2019;57(3):394-402.
Powell G, Kara V, Naranjo D, Kulkarni M, Best-Sule K, Coster T, Bonafede M, Gangadhar S, Kallenbach L, Bate A. Testing the Feasibility of a Digital Point of Care Solution for the Trusted near Real-Time Bidirectional Exchange of Novel and Informative Adverse Event Information. Ther Innov Regul Sci 2025; 59: 124–134.
Hoffman AR, Raveendran S, Manjelievskaia J, Komirenko AS, Winer I, Cheng J, Winer-Jones JP, Bonafede M, Miner P, Smith AR. Economic Burden of Growth Hormone Deficiency among Adults Who Are at Risk for and Who Have Confirmed Growth Hormone Deficiency Using US Real-World Data. J Med Econ 2025; 28: 1322–1333.
Hunter Gibble T, Chinthammit C, Ward JM, Cappell K, Sedgley R, Bonafede M, Liao B, Hankosky ER. Real-World Use of Tirzepatide among Individuals without Evidence of Type 2 Diabetes: Results from the Veradigm® Database. Diabetes Obes Metab 2025; 27: 3185–3194.
Hoffman AR, Raveendran S, Manjelievskaia J, Komirenko AS, Winer I, Cheng J, Bonafede M, Winer-Jones JP, Miner P, Smith AR. Prevalence, Treatment Patterns, and Characteristics of US Adults with Confirmed or at Risk for Growth Hormone Deficiency. Adv Ther 2025; 42: 2853–2873.
Kopel H, Nguyen VH, Bogdanov A, Winer I, Boileau C, Ducruet T, Zeng N, Winer-Jones JP, Esposito DB, Bausch-Jurken M, Beck E, Bonafede M, Mansi JA. Comparative Effectiveness of the Bivalent (Original/Omicron BA.4/BA.5) mRNA COVID-19 Vaccines Mrna-1273.222 andBNT162b2 Bivalent in Adults with Underlying Medical Conditions in the United States. Vaccines 2024; 12: 1107.
Kopel H, Araujo AB, Bogdanov A, Zeng N, Winer I, Winer-Jones J, Lu T, Marks MA, Bonafede M, Nguyen VH, Martin D, Mansi JA. Effectiveness of the 2023-2024 Omicron XBB.1.5-Containing mRNA COVID-19 Vaccine (mRNA-1273.815) in Preventing COVID-19-Related Hospitalizations and Medical Encounters among Adults in the United States. Open Forum Infect Dis 2024; 11: ofae695.
Imran M, Puig-Barbera J, Ortiz JR, Lopez-Gonzalez L, Dean A, Bonafede M, Haag MDM. Relative Effectiveness of the MF59®-Adjuvanted Influenza Vaccine versus High-Dose and Non-Adjuvanted Influenza Vaccines in Preventing Cardiorespiratory Hospitalizations during the 2019-2020 US Influenza Season. Influenza Other Respir Viruses 2024; 18: e13288.
Kopel H, Bogdanov A, Winer-Jones JP, Adams C, Winer IH, Bonafede M, Nguyen VH, Mansi JA. Comparison of COVID-19 and Influenza-Related Outcomes in the United States during Fall–Winter 2022–2023: A Cross-Sectional Retrospective Study. Diseases 2024; 12: 16.

BACK TO EXPERTS